This is a wonderful opportunity to express your thoughts about a new chelator and why you think it is needed and what this type of chelator could mean to the quality of your life. This survey is open to patients and parents because chelation is an issue that involves both. I have long believed that starch desferal (S-DFO) would be a chelator that would offer a solution to the non-compliance issue and provide an alternative to those who are tired of dealing with the many side effects of the current oral chelators and the nuisance and pain of nightly desferal injections. In other words, this is a chelator that most patients would seriously consider using if it was on the market. To get to market, funds need to be raised to run trials and for this, investors are needed. What you have to say about this chelator can have a strong effect on potential investors. Please think about what a one hour per week IV chelation that lasts all week would mean to your life. Think about how much easier combination chelation would be. Think about what chelation with very mild if any side effects would mean. Imagine using desferal without the subcutaneous injections, without the bumps, skin irritation and pain. This type of survey was done in our group before Exjade was marketed. The patients have a lot of influence on what can happen, so please be ambassadors for yourself and think about the prospects of long term chelation with the drug you currently use and whether you believe this is a permanent chelation solution for yourself or whether you will need a new chelator at some point. I think most will agree that a safer and easier to use chelator is greatly needed.
Biomedical Frontiers, a Minnesota based company founded by four University of Minnesota scientists, is preparing to enter Phase 2 Clinical Trials for a new drug therapy. This therapy has the potential to dramatically improve the quality of life for Thalassemia patients around the globe.
Biomedical Frontier's lead drug, S-DFO, is a long-acting intravenous iron chelator. Initial clinical study results suggest that a one hour, once a week infusion of S-DFO can replace the lengthy, burdensome regimen of current iron chelation therapy which involves daily drug infusions lasting between 8-12 hours.
Biomedical Frontier is launching a website to educate potential investors about S-DFO and the challenges patients face with current treatment programs. The company would like to share patient stories and perspectives on its website to tell a more compelling story to the investment community.
Would you be willing to share part of your story with the Biomedical Frontiers team? Your participation will help Biomedical Frontiers advance towards the next phase of commercializing this powerful new drug. Your story could be shared in a quick phone call or email and possibly be used on the company website. Confidentiality would be ensured.
(Because of uncertainty about FDA rules concerning direct contact with patients by drug companies, Janet has asked that her email address be removed and that people wishing to contact her, do so through me). You can help change the world.
Give your opinions, tell them your thoughts. You may have unique perspectives that only patients and parents would have. My observations over the years tell me that S-DFO would save many lives if it can get to the market and I have no doubt that Lisa and many others would still be alive today if this was available then. Lisa took a 4 hour IV of desferal once weekly and it was nowhere near enough, even combined with her subq desferal, which she could not take as often as needed due to the skin reaction and burning. This would have solved her problem. I think most of us knew someone who would still be here today if chelation had fewer and milder side effects. This is your chance to make something positive to happen.